Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Painting IMRT Plus Chemotherapy in Nasopharyngeal Carcinoma
NCT00052429Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2002
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin and fluorouracil in nasopharyngeal carcinoma (NPC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Survival Rate of Patients at 77 months and Local Control of Participants at 60 months. Started Sep 2002; status: completed.
02
Drugs
cisplatinfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00052429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00052429.